ATLANTA, April 16,
2024 /PRNewswire/ -- Annoviant™, Inc., a pioneering
company with a breakthrough TxGuard™ technology platform for
soft-tissue healing, currently focused on cardiovascular field,
proudly announces receipt of a $2.99
million grant (SBIR Phase 2b)
from the National Institutes of Health (NIH). This grant aims to
propel the development and commercialization of its revolutionary
TxGuard™ pulmonary valved conduit. Building upon the Phase II NIH
Grant secured in 2021, this funding represents a significant step
forward in Annoviant's mission to transform the landscape of
pediatric cardiac care.
Patented TxGuard™ stands at the forefront
of technological innovation in conduit replacements for treating
CHD.
Annoviant's patented TxGuard™ stands at the forefront of
technological innovation in conduit replacements for treating
congenital heart disease (CHD), the most prevalent birth defect
globally and a leading cause of birth-related mortality. CHD
encompasses a spectrum of abnormalities that disrupt blood flow to
and from the heart, affecting approximately 40,000 newborns
annually in the US and 1.35 million worldwide. With an estimated
2.9 million CHD patients in the US alone, the need for advanced
solutions is paramount.
Addressing critical shortcomings observed in current commercial
devices, TxGuard™ offers unparalleled clinical advantages, notably
its resistance to calcification, thrombosis, infection, and the
host cell integration. This cutting-edge technology heralds a new
era in pediatric cardiac interventions, providing durable pulmonary
valved grafts that adapt and regenerate alongside patients,
minimizing the need for multiple re-operations over their
lifetimes.
"We are delighted to receive this additional grant from the NIH,
accompanied by matching funds from our esteemed investors. This
marks a significant milestone for Annoviant as we accelerate our
pursuit of impactful innovation to save lives," said Ajay Houde, Ph.D., MBA, Co-Founder, and CEO of
Annoviant.
Pediatric patients with CHD often undergo multiple
cardiovascular surgeries throughout their lives, with associated
costs totaling billions for the US healthcare industry. TxGuard™
offers a transformative solution to this ongoing challenge,
promising extended durability and reduced healthcare burden for
patients and providers alike.
Dr. Naren Vyavahare, Ph.D.,
Annoviant's CTO, and Co-Founder, commented, "Pediatric CHD patients
require medical devices that can evolve with them into adulthood.
After fifteen years of dedicated research, we have developed
TxGuard™ technology to address this critical need, resisting
thrombosis and calcification while promoting host cell integration
and remodeling. With NIH Phase IIb funding, we look forward to
further refining pulmonary valved conduits for the benefit of CHD
patients."
About Annoviant
Founded in 2018, Annoviant™ is a
pioneering healthcare innovation company committed to the
development of transformative medical devices aimed at enhancing
and saving lives. Driven by the personal experiences of its
co-founders, Annoviant is fueled by an unwavering dedication to
positively impact the lives and treatment outcomes of congenital
heart disease (CHD) patients. At the heart of Annoviant's mission
is TxGuard™, a patented breakthrough innovation designed to heal
and adapt alongside patients battling life-threatening congenital
heart disease and other soft tissue applications. This portfolio of
patented breakthrough devices addresses numerous clinical
challenges, offering the potential to significantly reduce
healthcare costs by obviating the need for repetitive surgeries.
Annoviant actively collaborates with a diverse network, including
leading research institutions and industry partners nationwide, to
advance its innovative solutions. For further details, please visit
Annoviant.com.
NIH: Research reported in this news release was supported
by the National Heart, Lung, and Blood Institute (NHLBI) of the
National Institutes of Health (NIH) under Award Number
2R44HL147771-04. The content is solely the responsibility of the
authors and does not necessarily represent the official views of
the National Institutes of Health.
For media inquiries or further information, please contact:
Annoviant Media Relations
pr@annoviant.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/annoviant-awarded-2-99-million-nih-grant-to-advance-txguard-pulmonary-valved-conduit-for-pediatric-heart-disease-302117378.html
SOURCE Annoviant